There are 444 resources available
How can we optimise the use of immunotherapy for driver+ NSCLC: Are all targets the same?
Presenter: Tony S.K. Mok
Session: Best therapies with driver mutations in lung cancer
Resources:
Slides
Webcast
Q&A and discussion
Session: Challenges of brain metastases: The patient’s perspective (Patient advocacy session)
Resources:
Webcast
Q&A and discussion
Session: AI application in diagnosis and pathology
Resources:
Webcast
Q&A and discussion
Session: Best therapies with driver mutations in lung cancer
Resources:
Webcast
Incorporating ctDNA and other plasma-based assays into clinical trial design
Presenter: Maximilian Diehn
Session: Incorporating ctDNA and other plasma-based assays into clinical trial design
Resources:
Slides
Webcast
Welcome and introduction
Presenter: Egbert Smit
Session: Daiichi Sankyo - Targeting rare mutations in NSCLC: A focus on HER2m
Resources:
Webcast
New approaches to augment early detection
Presenter: Anne-Marie Baird
Session: Advances in the lung cancer pathway (Patient advocacy session)
Resources:
Slides
Webcast
Small numbers, big impact: The importance of testing for rare mutations in mNSCLC
Presenter: Luka Brcic
Session: Daiichi Sankyo - Targeting rare mutations in NSCLC: A focus on HER2m
Resources:
Webcast
Liquid biopsy: Where are we?
Presenter: JORDI REMON MASIP
Session: Advances in the lung cancer pathway (Patient advocacy session)
Resources:
Slides
Webcast
The evolving treatment landscape for rare mutations: Focus on HER2m
Presenter: Sonja Loges
Session: Daiichi Sankyo - Targeting rare mutations in NSCLC: A focus on HER2m
Resources:
Webcast